Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of EarningsStock Story·1 day ago, 10:10 PMAMRX+1.81%
Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)Tip Ranks·2 days ago, 06:37 AMAMRX+1.81%
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the FirmMorningStar·Jul 23 at 12:44 PMAMRX+1.81%
UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring WinnersZeroHedge·Jul 22 at 08:45 AMTEVA+9.60%VTRS-0.22%
5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & Morerttnews·Jul 19 at 12:05 PMAMRX+1.81%PSNL-1.26%
Amneal wins FDA approval for additional iohexol injection strengths and vial sizesPUBT·Jul 17 at 07:02 AMAMRX+1.81%
Amneal Pharmaceuticals to report second-quarter 2026 results, host webcastPUBT·Jul 9 at 03:05 PMAMRX+1.81%
Amneal, Adalvo win FDA review acceptance for generic tirzepatide autoinjector ANDAsPUBT·Jul 8 at 03:14 PMAMRX+1.81%
Alkermes Ends Generic VIVITROL Supply Agreement with AmnealTip Ranks·Jul 8 at 07:30 AMAMRX+1.81%ALKS-4.28%
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?Simplywall·Jul 7 at 10:54 PMAMRX+1.81%
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced?Simplywall·Jul 3 at 11:13 AMAMRX+1.81%
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations | AMRX Stock NewsStockTitan·Jun 28 at 06:00 PMAMRX+1.81%
